How J&J's Innovative Medicines Segment is Poised Ahead of Q3 Results
JNJ's Innovative Medicine sales face biosimilar pressure and IRA headwinds, but growth drivers like Darzalex, Tremfya and Erleada may have ensured steady Q3 momentum.
Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus
Amneal Pharmaceuticals, Leidos and Vishay Precision stand out as Zacks highlights amid market volatility and shifting rate expectations.
Johnson & Johnson ( JNJ ) Rises Higher Than Market: Key Facts
Johnson & Johnson (JNJ) closed the most recent trading day at $188.64, moving +1.43% from the previous trading session.
Johnson & Johnson's Options Frenzy: What You Need to Know - Johnson & Johnson ( NYSE:JNJ )
Investors with a lot of money to spend have taken a bearish stance on Johnson & Johnson ( NYSE:JNJ ) . We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't ...
Coinbase To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Friday - Antero Resources ( NYSE:AR ) , AeroVironment ( NASDAQ:AVAV )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Jefferies cut Antero Resources Corporation ( NYSE:AR ) price target from $50 to $47.
This Johnson & Johnson Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Duke Energy ( NYSE:DUK ) , Curbline Properties ( NYSE:CURB )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V. - XOMA Royalty ( NASDAQ:XOMA ) , LAVA Therapeutics ( NASDAQ:LVTX )
EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 ( GLOBE NEWSWIRE ) -- XOMA Royalty Corporation ( "XOMA Royalty" ) ( NASDAQ:XOMA ) and LAVA Therapeutics N.V. ( "LAVA" ) ( NASDAQ:LVTX ) today announced the extension of the expiration of the tender offer to purchase ...
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
XOMA Royalty extends its tender offer for LAVA Therapeutics.
Dentsply Sirona Appoints Aldo M. Denti as Chief Commercial Officer and Announces Customer-Centric Organization
CHARLOTTE, N.C., Oct. 02, 2025 ( GLOBE NEWSWIRE ) -- DENTSPLY SIRONA Inc. ( "Dentsply Sirona" or the "Company" ) ( Nasdaq: XRAY ) today announced that Aldo M. Denti has been appointed Executive Vice President and Chief Commercial Officer ( CCO ) , effective October 6, 2025.
Dentsply Sirona Appoints Aldo M. Denti as Chief Commercial Officer and Announces Customer-Centric Organization - Dentsply Sirona ( NASDAQ:XRAY )
CHARLOTTE, N.C., Oct. 02, 2025 ( GLOBE NEWSWIRE ) -- DENTSPLY SIRONA Inc. ( "Dentsply Sirona" or the "Company" ) ( NASDAQ:XRAY ) today announced that Aldo M. Denti has been appointed Executive Vice President and Chief Commercial Officer ( CCO ) , effective October 6, 2025.
Tesla Stock Climbs Nearly 2% In Thursday Pre-Market: What's Going On? - Tesla ( NASDAQ:TSLA )
Tesla Inc. ( NASDAQ:TSLA ) stock climbed 1.86% during Thursday's pre-market trading session after CEO Elon Musk reached an unprecedented financial milestone to become the first person in history to amass a net worth of $500 billion.
Elon Musk Becomes First Person Worth $500 Billion, Tesla CEO's Wealth Is Now Larger Than Palantir, Alibaba - Alibaba Gr Hldgs ( NYSE:BABA ) , Johnson & Johnson ( NYSE:JNJ )
Elon Musk has achieved yet another historic milestone, becoming the first person in history to be worth $500 billion, driven by Tesla Inc.'s ( NASDAQ:TSLA ) stock rally, SpaceX's soaring valuations, and the growing value of his AI venture, xAI Holdings.
NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 ( NBTXR3 ) for Patients With Esophageal Cancer
Data presented at the 2025 Annual Meeting of the American Society for Radiation Oncology ( ASTRO ) on October ...
ISRG Expands SP Indications: A Game Changer in Colorectal Surgery?
Intuitive Surgical's SP platform secures new colorectal clearances, with 88% growth in procedures and rising global adoption momentum.
Trump's pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers
Pfizer's deal with Trump was a relief to the pharma industry, signaling that drugmakers could strike similar deals that would make them immune to tariffs.
Unlocking Cures: How AI is Reshaping Cancer Research & Healthcare ETFs?
AI's growing role in cancer research, and a new federal push for pediatric oncology, are powering gains in key healthcare ETFs.
Should You Buy Kenvue Stock After Its 30% Plunge?
There hasn't been much good news lately for this Johnson & Johnson spinoff.
Stock Market Today: Pfizer Rallies on Trump Drug Pricing Deal and U.S. Investment Pledge
Pfizer surged after striking a landmark agreement with the Trump administration to lower drug prices and expand U.S. production.
The Beauty Health Company Names Pedro Malha President and Chief Executive Officer - Beauty Health ( NASDAQ:SKIN )
Global Healthcare and Medical Device Executive with More Than 20 Years of Experience Assumes Role Effective October 1 Marla Beck Steps Down, With BeautyHealth Prepared for Its Next Phase of Growth
NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results - Nanobiotix ( NASDAQ:NBTX )
PARIS and CAMBRIDGE, Mass., Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- NANOBIOTIX ( NASDAQ:NBTX ) , a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, provided an update on operational ...
NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results
PARIS and CAMBRIDGE, Mass., Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- NANOBIOTIX ( Euronext: NANO - NASDAQ: NBTX - the "Company" ) , a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, ...
Why Is Nanobiotix Stock Surging Tuesday? - Nanobiotix ( NASDAQ:NBTX )
Nanobiotix SA ( NASDAQ:NBTX ) on Tuesday announced updated data from cohorts 1 and 2 of Study 1100 Phase 1 dose escalation and expansion trial evaluating JNJ-1900 ( NBTXR3 ) activated by radiation therapy ( RT ) followed by anti-PD-1 immune checkpoint inhibitors ( ICI ) in patients with ...
LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025
Additional time enables LAVA Therapeutics to address potential liabilities and confirm net cash to be delivered to Shareholders. LAVA Therapeutics and XOMA Royalty anticipate closing the announced acquisition in the fourth quarter of 2025.
LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025 - LAVA Therapeutics ( NASDAQ:LVTX )
Additional time enables LAVA Therapeutics to address potential liabilities and confirm net cash to be delivered to Shareholders. LAVA Therapeutics and XOMA Royalty anticipate closing the announced acquisition in the fourth quarter of 2025.
Should Franklin U.S. Low Volatility High Dividend Index ETF ( LVHD ) Be on Your Investing Radar?
Style Box ETF report for ...
Want Reliable Passive Income? 1 ETF to Buy Right Now.
This dividend fund trades at a 35% valuation discount to the S&P 500 while delivering 11.5% annual returns over the past 10 years.
NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 ( NBTXR3 ) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC
Data presented as a "Top-rated Abstract in Head and Neck Cancer" at the 2025 Annual Meeting of the American Society for Radiation Oncology ( ASTRO ) on September ...
NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 ( NBTXR3 ) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC - Nanobiotix ( NASDAQ:NBTX )
Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïve or resistant to anti-PD-1 63% ( 26/41 ) disease control rate ( "DCR" ) and 37% ( 15/41 ) objective response rate ( "ORR" ) in evaluable anti-PD-1 naïve patients per ...
Why Johnson & Johnson Could Be the Ultimate Dividend King
Johnson & Johnson has increased its dividend every year for 63 consecutive years. It doesn't want to stop.
Is Palantir Technologies Stock a Buy Now?
The stock is once again nearing an all-time high, but the valuation is untenable.
These 3 ETFs Could Shine as Interest Rates Fall
These ETFs hold dividend-paying stocks that should do well with interest rates dropping.
Johnson & Johnson ( JNJ ) Surpasses Market Returns: Some Facts Worth Knowing
Johnson & Johnson (JNJ) closed at $179.71 in the latest trading session, marking a +1.11% move from the prior day.
Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE?
ABBV eyes a 2025 rebound as Skyrizi and Rinvoq drive growth beyond Humira, with oncology and neuroscience adding momentum.
Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit
Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.
Could This Single Dividend King Make Your Portfolio Worth $1 Million in 20 Years?
There is a lot to like about this healthcare company, but that goal might be beyond its powers.
Is Invesco Dow Jones Industrial Average Dividend ETF ( DJD ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity - Johnson & Johnson ( NYSE:JNJ )
Financial giants have made a conspicuous bullish move on Johnson & Johnson. Our analysis of options history for Johnson & Johnson ( NYSE: JNJ ) revealed 17 unusual trades. Delving into the details, we found 58% of traders were bullish, while 23% showed bearish tendencies.
What's Driving the Market Sentiment Around Johnson & Johnson? - Johnson & Johnson ( NYSE:JNJ )
Johnson & Johnson's ( NYSE: JNJ ) short interest as a percent of float has risen 17.95% since its last report. According to exchange reported data, there are now 22.05 million shares sold short, which is 0.92% of all regular shares that are available for trading.
Will BDTX's EGFR Inhibitor Bring a Paradigm Shift in NSCLC Treatment?
Black Diamond's silevertinib aims to challenge Tagrisso, offering broad EGFR mutation coverage, as key trial results are expected in late 2025.
Johnson & Johnson ( JNJ ) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Investors Heavily Search Johnson & Johnson ( JNJ ) : Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Is iShares Core High Dividend ETF ( HDV ) a Strong ETF Right Now?
Smart Beta ETF report for ...
These 3 Dow Stocks Are Set to Soar in 2025 and Beyond
The proverbial planets are aligning for each of their underlying companies.
3 Exceptional High-Yielding Dividend Kings That Have Been Increasing Their Payouts for Over 60 Years
Not only have these stocks raised their dividends consistently, but they also offer above-average yields.
Financière de Tubize strengthens its expertise in the biopharma field by appointing 2 new directors
Since the appointment of Bruno Holthof as Chairman of the Board of Directors of the company in April 2025, the company's board has continued to strengthen its expertise in the biopharma field.
Should You Invest in Johnson & Johnson ( JNJ ) Based on Bullish Wall Street Views?
Based on the average brokerage recommendation (ABR), Johnson & Johnson (JNJ) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Robotics and MedSurg Drive Stryker Growth Amid Margin Pressures
SYK posts 11% sales growth and EPS beat for Q2, driven by Mako robotics and MedSurg strength, but faces cost and margin headwinds.
What's Going On With Jabil Stock Tuesday? - Jabil ( NYSE:JBL )
Jabil Inc. JBL is set to report its fiscal fourth-quarter earnings on Thursday, September 25, with investor focus squarely on its outlook for fiscal 2026, particularly AI and cloud-related revenue. Bank of America expects the company to issue its usual conservative guidance for the year ahead, in ...
This Johnson & Johnson Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Antero Resources ( NYSE:AR ) , Alvotech ( NASDAQ:ALVO )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Johnson & Johnson Ends Overseas Sales Of Acid Reflux Device Citing Market Factors Johnson & Johnson Will Stop Overseas Sales Of Gerd Medication - Johnson & Johnson ( NYSE:JNJ )
Johnson & Johnson JNJ is reportedly halting international sales of its Linx Reflux Management System, a device used to treat chronic acid reflux. In a letter to doctors dated September 17, the company stated that sales outside the U.S. will cease at the end of March.
